Kaempferol 3-O-sophoroside

Name: Kaempferol 3-O-sophoroside
Brand: MedChemExpress
SKU: HY-N2055
Rating: 4.5 (1 reviews)

Cat. No.: HY-N2055 Purity: 99.84%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Kaempferol 3-O-sophoroside is an orally active derivative of Kaempferol. It exhibits anti-inflammatory, analgesic, and antidepressant effects. Kaempferol 3-O-sophoroside is an inhibitor of the cell surface receptor toll-like receptor (TLR) 2/4 for High mobility group box 1 (HMGB1), and it also exerts anti-inflammatory effects by blocking the activation of NF-κB expression and the production of TNF-α. Kaempferol 3-O-sophoroside promotes the production of brain-derived neurotrophic factor (BDNF) and enhances autophagy by binding to AMP-activated protein kinase (AMPK), thereby exerting antidepressant effects. Kaempferol 3-O-sophoroside holds promise for research in the fields of inflammation and neurodegenerative diseases.

For research use only. We do not sell to patients.

Kaempferol 3-O-sophoroside Chemical Structure

CAS No. : 19895-95-5

Size	Price	Stock	Quantity
1 mg	USD 95	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 250	In-stock	Estimated Time of Arrival: December 31
10 mg		Get quote
50 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms

TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All TNF Receptor Isoform Specific Products:

View All Isoforms

TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All AMPK Isoform Specific Products:

View All Isoforms

NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

TLR2

TLR4

In Vitro

Kaempferol 3-O-sophoroside (5 μM, 48 h) does not affect the cell viability of human umbilical vein endothelial cells (HUVECs)^[1].
Kaempferol 3-O-sophoroside (0-5 μM, 3 h) dose-dependently reduces barrier disruption in lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs), while it does not alter the integrity of the cell barrier when used alone^[1].
Kaempferol 3-O-sophoroside (0-5 μM, 24 h) inhibits neutrophil adhesion to lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs) and suppresses neutrophil migration to HUVECs by blocking the activation of NF-κB and the production of TNF-α^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs)
Concentration:	0.005, 0.05, 0.5, 5 μM
Incubation Time:	48 h
Result:	Did not effect cell via- bility At the concentration used (5 μM).

Cell Migration Assay ^[1]

Cell Line:	Lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs)
Concentration:	0, 0.005, 0.05, 0.5, 5 μM
Incubation Time:	24 h
Result:	Inhibited the binding of neutrophils to Lipopolysaccharides (HY-D1056)-stimulated endothelial cells and the transendothelial migration (TEM) of neutrophils.

In Vivo

Kaempferol 3-O-sophoroside (10 and 20 mg/kg, p.o., once daily for 20 days) binds to AMP-activated protein kinase (AMPK) to promote brain-derived neurotrophic factor (BDNF) production and autophagy enhancement in corticosterone (HY-B1618)-induced mouse depression model and chronic unpredictable mild stress (CUMS) model, ultimately achieving antidepressant effects^[3].
Kaempferol 3-O-sophoroside (100 and 200 mg/kg, p.o., 30-minute administration duration) exhibits analgesic effects in the acetic acid-induced writhing mice model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Acetic acid-induced writhing mice model^[4]
Dosage:	50, 100, 200 mg/kg
Administration:	Oral gavage (p.o.), administration duration of 30 minutes
Result:	Caused dose-dependent inhibition of the writhing response induced by acetic acid.

Animal Model:	Corticosterone (HY-B1618)-induced mouse depression model; Chronic unpredictable mild stress (CUMS) model^[3]
Dosage:	10 and 20 mg/kg
Administration:	Oral gavage (p.o.), once per day for 20 consecutive days
Result:	Ameliorated weight loss, dyskinesia, and hippocampal volume reduction induced by Corticosterone and CUMS.

Molecular Weight

610.52

Formula

C₂₇H₃₀O₁₆

CAS No.

19895-95-5

Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C1C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)=C(C4=CC=C(O)C=C4)OC5=CC(O)=CC(O)=C15

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (163.79 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6379 mL	8.1897 mL	16.3795 mL
5 mM	0.3276 mL	1.6379 mL	3.2759 mL
10 mM	0.1638 mL	0.8190 mL	1.6379 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.84%

Select Batch:

Data Sheet (300 KB) SDS (252 KB)

COA (259 KB) HNMR (251 KB) CNMR (229 KB) RP-HPLC (365 KB) MS (592 KB)

Handling Instructions (2659 KB)

References

[1]. Kim TH, et al. Anti-inflammatory effects of kaempferol-3-O-sophoroside in human endothelial cells. Inflamm Res. 2012 Mar;61(3):217-24. [Content Brief]

[2]. Kim T H, et al. Inhibitory effects of kaempferol-3-O-sophoroside on HMGB1-mediated proinflammatory responses[J]. Food and chemical toxicology, 2012, 50(3-4): 1118-1123. [Content Brief]

[3]. Wang R, et al. Kaempferol‐3‐O‐sophoroside (PCS‐1) contributes to modulation of depressive‐like behaviour in C57BL/6J mice by activating AMPK[J]. British journal of pharmacology, 2024, 181(8): 1182-1202. [Content Brief]

[4]. Parveen Z, et al. Antiinflammatory and analgesic activities of Thesium chinense Turcz extracts and its major flavonoids, kaempferol and kaempferol-3-O-glucoside[J]. Yakugaku Zasshi, 2007, 127(8): 1275-1279. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6379 mL	8.1897 mL	16.3795 mL	40.9487 mL
	5 mM	0.3276 mL	1.6379 mL	3.2759 mL	8.1897 mL
	10 mM	0.1638 mL	0.8190 mL	1.6379 mL	4.0949 mL
	15 mM	0.1092 mL	0.5460 mL	1.0920 mL	2.7299 mL
	20 mM	0.0819 mL	0.4095 mL	0.8190 mL	2.0474 mL
	25 mM	0.0655 mL	0.3276 mL	0.6552 mL	1.6379 mL
	30 mM	0.0546 mL	0.2730 mL	0.5460 mL	1.3650 mL
	40 mM	0.0409 mL	0.2047 mL	0.4095 mL	1.0237 mL
	50 mM	0.0328 mL	0.1638 mL	0.3276 mL	0.8190 mL
	60 mM	0.0273 mL	0.1365 mL	0.2730 mL	0.6825 mL
	80 mM	0.0205 mL	0.1024 mL	0.2047 mL	0.5119 mL
	100 mM	0.0164 mL	0.0819 mL	0.1638 mL	0.4095 mL